According to Orient's announcement, three departments including the National Health and Health Commission issued a notice that the company's main drug, didroprogesterone tablets, was added to the “National Essential Drug Catalogue”. The catalogue will take effect on September 1, 2026. Didrogesterone tablets can be used to treat diseases caused by endogenous progesterone deficiency. This addition to the basic drug catalogue is beneficial to drug promotion and has a positive effect on the company's market expansion and long-term development, but subsequent sales are affected by multiple factors, and there is uncertainty.

According to Orient's announcement, three departments including the National Health and Health Commission issued a notice that the company's main drug, didroprogesterone tablets, was added to the “National Essential Drug Catalogue”. The catalogue will take effect on September 1, 2026. Didrogesterone tablets can be used to treat diseases caused by endogenous progesterone deficiency. This addition to the basic drug catalogue is beneficial to drug promotion and has a positive effect on the company's market expansion and long-term development, but subsequent sales are affected by multiple factors, and there is uncertainty.